Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 4/20 | 0.32 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.32 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.32 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.32 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.30 |
| ▸ | PRKDC | P78527 | 1/20 | 0.30 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15603753 | 0.90 | PIK3CA (0.32) | PIK3CAPIK3CDPIK3CBPIK3CGPIK3C3 | |
| SCHEMBL7863852 | 0.81 | PIK3C3 (0.32) | PIK3CAPIK3C3 | |
| SCHEMBL859404 | 0.81 | PIK3CA (0.37) | PIK3CAPIK3CDPIK3CBPIK3CG | |
| SCHEMBL858509 | 0.78 | PIK3CA (0.33) | PIK3CAPIK3CDPIK3CBPIK3CGNTRK1 | |
| SCHEMBL3761313 | 0.78 | PIK3CA (0.37) | PIK3CAPIK3CDPIK3CBPIK3CGPRKDC | |
| SCHEMBL858852 | 0.78 | PRKDC (0.35) | PIK3CAPIK3CDPIK3CBPIK3CGPIK3C3 | |
| SCHEMBL859013 | 0.78 | USP30 (0.36) | PIK3CAPIK3CDPIK3CBPIK3CG | |
| SCHEMBL3758492 | 0.77 | PIK3CA (0.32) | PIK3CAPIK3CDPIK3CBPIK3CGNTRK1 | |
| SCHEMBL858783 | 0.77 | PIK3CA (0.32) | PIK3CA | |
| SCHEMBL856436 | 0.76 | PIK3C3 (0.43) | PIK3CAPIK3CDPIK3CBPIK3CGPIK3C3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140080810-A1 | Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture | EXELIXIS, INC. (US) | 2014-03-20 | — | — | US | disclosed |
| US-20140080810-A1 | Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture | EXELIXIS, INC. (US) | 2014-03-20 | — | — | US | disclosed |
| WO-2010135524-A1 | BENZOXAZEPINES BASED P13K/MT0R INHIBITORS AGAINST PROLIFERATIVE DISEASES | EXELIXIS, INC. (US) | 2010-11-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140080810-A1 | Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture | MTOR, RICTOR, PIK3CA | PIK3CA 3/4885PIK3CD 4/4885PIK3CB 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.